FAPI-PET/CT in Psoriatic Arthritis

• Status: Recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease. Therefore, this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for disease activity assessment and follow-up of psoriatic arthritis than 18F-NAF PET/CT.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• fulfilled the 2006 Classification Criteria for Psoriatic Arthritis (CASPAR)

• 18F-NAF PET/CT within two weeks

• signed written consent.

Exclusion Criteria:

• pregnancy

• breast feeding

• known allergy against FAPI

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.